anticoagulant

Businessman climbing steps to pluck a star from the sky
Biotech

Bayer's asundexian cuts stroke risk in phase 3

Asundexian significantly reduced the risk of stroke, boosting a potentially blockbuster mechanism that has suffered setbacks over the past two years.
Nick Paul Taylor Nov 24, 2025 6:25am
Cartoon of businessmen standing around a broken target

BMS-J&J blood thinner fails phase 3, denting blockbuster hopes

Nov 14, 2025 8:10am
Glowing puzzle piece fitting into puzzle

CSL pays $117M for option on phase 3 blood clotting specialist

Sep 16, 2025 4:31am
pass the torch deal sell buy acquisition

Novartis inks $925M Anthos takeover to rejoin clot-busting race

Feb 11, 2025 5:21am
Graphic of a drop of blood made up of small data points and nodes

Regeneron anticoagulant bests enoxaparin, matches Eliquis

Dec 19, 2024 8:50am
visual of red blood cells

Blackstone's $250M bet beats Xarelto in phase 2 bleeding trial

Sep 18, 2023 6:00am